We are live on
!
Find out more
BB
BB Biotech Portfolio holdings
AUM
$3.98B
1-Year Est. Return
15.47%
This Fund
S&P 500
This Quarter
Est. Return
+15.43%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$1.39B
AUM Growth
–
Cap. Flow
+$1.36B
Cap. Flow
% of AUM
97.66%
Top 10 Holdings %
Top 10 Hldgs %
84.97%
Holding
23
New
23
Increased
–
Reduced
–
Closed
–
Avg Time Held
0
quarters
Top 10 Avg Time Held
0
quarters
Top 20 Avg Time Held
0
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$259M |
| 2 |
Gilead Sciences
GILD
|
+$193M |
| 3 |
Ionis Pharmaceuticals
IONS
|
+$165M |
| 4 |
Incyte
INCY
|
+$117M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$103M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.98% |
| 2 | Miscellaneous | 11.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $252M | 18.12% |
+4,300,372
| New | +$259M |
2013 Q2
0 quarters
|
|
|
2
Ionis Pharmaceuticals
IONS
$7.52B
| $209M | 15.04% |
+7,769,172
| New | +$165M |
2013 Q2
0 quarters
|
|
|
3
Gilead Sciences
GILD
$187B
| $190M | 13.67% |
+3,700,000
| New | +$193M |
2013 Q2
0 quarters
|
|
|
4
Incyte
INCY
$22.9B
| $118M | 8.49% |
+5,357,149
| New | +$117M |
2013 Q2
0 quarters
|
|
|
5
Vertex Pharmaceuticals
VRTX
$129B
| $112M | 8.1% |
+1,404,445
| New | +$103M |
2013 Q2
0 quarters
|
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $71.8M | 5.17% |
+778,126
| New | +$75M |
2013 Q2
0 quarters
|
|
|
MDVN
7
DELISTED
MEDIVATION, INC.
MDVN
| $71.3M | 5.14% |
+2,899,412
| New | +$73M |
2013 Q2
0 quarters
|
|
|
ARIA
8
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $54.5M | 3.93% |
+3,115,371
| New | +$55.2M |
2013 Q2
0 quarters
|
|
9
DELISTED
Immunogen Inc
IMGN
| $54.1M | 3.9% |
+3,262,094
| New | +$52.9M |
2013 Q2
0 quarters
|
|
|
ONXX
10
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
| $47.4M | 3.42% |
+546,500
| New | +$50.3M |
2013 Q2
0 quarters
|
|
11
Halozyme
HALO
$12.5B
| $44.9M | 3.23% |
+5,646,519
| New | +$36M |
2013 Q2
0 quarters
|
|
12
Innoviva
INVA
$1.53B
| $34.2M | 2.47% |
+1,102,311
| New | +$29.6M |
2013 Q2
0 quarters
|
|
|
ECYT
13
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $30.7M | 2.21% |
+2,339,345
| New | +$31.5M |
2013 Q2
0 quarters
|
|
|
OPTR
14
DELISTED
OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR
| $20.9M | 1.51% |
+1,446,700
| New | +$21.1M |
2013 Q2
0 quarters
|
|
|
INFI
15
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $17.6M | 1.27% |
+1,089,828
| New | +$33.7M |
2013 Q2
0 quarters
|
|
16
Alnylam Pharmaceuticals
ALNY
$31.1B
| $14.1M | 1.02% |
+454,800
| New | +$12.1M |
2013 Q2
0 quarters
|
|
|
ACHN
17
DELISTED
Achillion Pharmaceuticals
ACHN
| $13.7M | 0.99% |
+1,679,340
| New | +$12.8M |
2013 Q2
0 quarters
|
|
18
BioMarin Pharmaceuticals
BMRN
$10.6B
| $9.92M | 0.71% |
+178,028
| New | +$11.1M |
2013 Q2
0 quarters
|
|
|
MDCO
19
DELISTED
Medicines Co
MDCO
| $9.32M | 0.67% |
+302,993
| New | +$10.1M |
2013 Q2
0 quarters
|
|
|
IDIX
20
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
| $4.51M | 0.33% |
+1,250,000
| New | +$5.11M |
2013 Q2
0 quarters
|
|
|
DNDN
21
DELISTED
DENDREON CORPORATION
DNDN
| $4.18M | 0.3% |
+1,014,800
| New | +$4.32M |
2013 Q2
0 quarters
|
|
|
TSRX
22
DELISTED
TRIUS THERAPEUTICS INC COM STK (DE)
TSRX
| $2.27M | 0.16% |
+280,000
| New | +$2.07M |
2013 Q2
0 quarters
|
|
|
GEVA
23
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $2.25M | 0.16% |
+53,549
| New | +$2.44M |
2013 Q2
0 quarters
|
|
Similar funds
SBAM
HFS
SA
WF
BCPEM
DCM
AB
MFBTD
BB Biotech's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for BB Biotech, which disclosed 23 positions worth $1.39B. Its ten largest holdings account for 85% of the portfolio.
Its largest position is Celgene Corp: 4,300,372 shares worth $252M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, followed by Miscellaneous.
- BB Biotech's largest Q2 2013 buy was Celgene Corp: 4,300,372 shares worth $252M.
- BB Biotech's ten largest holdings make up 85% of its $1.39B portfolio in Q2 2013.
- BB Biotech disclosed 23 positions in Q2 2013, its first 13F filing on record.
Based on BB Biotech's 13F filing for Q2 2013, filed 14 Aug 2013.